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A robust new analytical method has been developed for the determination of 5-fluorouracil
(5-FU) in human plasma samples using high-performance liquid chromatography-tandem
mass spectrometry (HPLC-MS/MS). The method is based on a liquid–liquid extraction
procedure, precolumn derivatization, reversed-phase HPLC separation, and detection using
atmospheric pressure chemical ionization and selected reaction monitoring. The derivatization
agent used was 4-bromomethyl-7-methoxycoumarin. The internal standard for the assay
procedure was a stable isotope labeled analog of 5-FU. The lower limit of quantitation was 1.0
ng/mL using 500 mL aliquots of plasma. Sample throughput on the mass spectrometer was
approximately 17 samples/h (3.5 min/sample). The method was fully validated. The recovery
of 5-FU averaged 76.1%. The accuracy of the assay, assessed from quality control samples,
ranged from 99.1% to 104.3% (% theoretical). The overall interassay precision (% RSD) was
2.7%, and the intraassay precision (% RSD) ranged from 1.5% to 3.9%. The derivatized samples
were found to be stable under sample analysis conditions and during refrigerator storage. The
method was specific for the determination of 5-FU. (J Am Soc Mass Spectrom 1998, 9,
970–976) © 1998 American Society for Mass Spectrometry
5-Fluorouracil (5-FU) (Figure 1) has been estab-lished as a successful cytostatic agent in the che-motherapeutic treatment of tumors for many
years. It is still one of the most commonly used antican-
cer drugs [1–3]. In order to obtain information for
therapeutic monitoring and scientific research, the de-
velopment of a practical, reliable, and rapid analytical
method for determination of plasma concentrations of
5-FU was important. Among many published analytical
methods, HPLC/UV was most popularly used for de-
termination of 5-FU in plasma, serum, tissue, and urine
samples, and the detection limit was typically 50
ng/mL or higher [4–6]. However, in several articles,
detection limits of 2–10 ng/mL were reported [7–9]. The
detection limit for determination of 5-FU with the more
sensitive gas chromatography/mass spectrometry
(GC/MS) methods [10–12] was reported at the 0.5–1
ng/mL level. High-pressure liquid chromatography
(HPLC)/fluorescence methods with derivatization [13,
14] reported impressive sensitivity from 0.5 ng/mL
down to the fmol level of detection. With the develop-
ment of prodrugs of 5-FU [15–18], analytical methods
with high sensitivity, fast assay speed and, in some
cases, use of less plasma volume were preferred. Dur-
ing recent years, the use of LC/MS technology has
shown a strong tendency to replace the use of HPLC/
UV, HPLC/fluorescence, and GC/MS in drug analysis.
In fact, integration with advanced technology is becom-
ing an essential criteria for analytical method develop-
ment.
This paper describes a new liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method for
the determination of 5-FU, which utilizes selected reac-
tion monitoring (SRM) and precolumn derivatization to
achieve high sensitivity, specificity, and rapid results.
Experimental
Chemicals and Sample Preparation Materials
5-Fluorouracil was obtained from the Quality Control
Department, Hoffmann-La Roche, Nutley, NJ. An ana-
log of 5-FU containing two 15N stable isotopes (5-FU–
15N2) was synthesized for use as an internal standard by
the Physical Chemistry Department of Hoffmann-La
Roche. The radioactive isotope, 5-FU–2-14C, and 18-
crown-6 were purchased from SIGMA Chemical Com-
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pany, St. Louis, MO. Acetic acid, ACS grade; ammo-
nium acetate, ACS grade; acetonitrile, HPLC grade;
ethyl acetate, HPLC grade; acetone, HPLC grade; and
n-hexane, HPLC grade, were obtained from Fisher
Scientific, Fair Lawn, NJ. Distilled water was purified to
18 MOhm resistivity with a Milli-Q UF Plus water
purification unit, Millipore Corp., Bedford, MA. Potas-
sium carbonate was purchased from J. T. Baker, Phil-
lipsburg, NJ. 4-Bromomethyl-7-methoxycoumarin was
purchased from Regis Technologies, Morton Grove, IL.
Molecular sieves, 4 Å, were purchased from Davison
Chemical, Baltimore, MD. Drug-free, control human
plasma, collected using EDTA anticoagulant, was ob-
tained from Rockland, Gilbertsville, PA.
The following materials and equipment were used
for sample preparation: 16 3 100 mm disposable culture
tubes, Micro-Centrifuge Model 235B, and Fisher Vortex
Genie 2, Fisher Scientific, Fair Lawn, NJ; TurboVap LV
evaporator, Zymark, Hopkinton, MA; IEC HN-SII cen-
trifuge, Damon/IEC Division, International Equipment,
Needham, MA; Gilson Pipetman and tips, Rainin In-
strument, Woburn, MA; Eppendorf repeating pipette
and tips, Brinkmann Instruments, Westbury, NY; Mi-
cro-Spin centrifuge filters, 0.22 mm, Nylon 66, Alltech
Associates, Deerfield, IL; and IKA-Vibrax-VXR shaker,
IKA Labortechnik Staufen, 79219 Staufen, Germany.
Instrumentation and Analytical Conditions
The HPLC system included a Beckman Model 116
System Gold pump, Beckman Instruments, San Ramon,
CA and a Waters 717 Plus autosampler, Millipore,
Milford, MA. The analytical column was a Zorbax
SB-C18, 4.6 mm 3 7.5 cm, particle size 3.5 mm, MAC-
MOD Analytical, Chadds Ford, PA. The isocratic mo-
bile phase was composed of acetonitrile: aqueous am-
monium acetate, 0.01 M, pH 4.5 (65:35, v/v). The
ammonium acetate buffer was adjusted to pH 4.5 using
glacial acetic acid and a pH meter. The flow rate was
maintained at 1.0 mL/min. The HPLC column temper-
ature was ambient.
A PE Sciex API III Plus mass spectrometer, with the
associated PE Sciex Macintosh data system (PE Sciex,
Thornhill, Ontario, Canada), was operated in positive
ionization atmospheric pressure chemical ionization
(APCI) mode. Instrument tuning parameters were op-
timized using a 200-mL/min infusion of a 10-mg/mL
solution of derivatized 5-FU in acetonitrile: aqueous
ammonium acetate, 0.01 M, pH 4.5 (65:35, v/v). The
APCI probe temperature was 500°C, and the current
applied to the corona discharge needle was 3 mA. The
nebulizing and auxiliary gases were high purity nitro-
gen delivered from a Dewar liquid nitrogen vessel at 70
psi and 2 L/min, respectively. The curtain gas (0.6
L/min) was also high purity nitrogen from a Dewar
vessel. The orifice was set at 50 V. The instrument was
operated in selected reaction monitoring (SRM) mode,
with both quadrupoles set at unit mass resolution (peak
width of precursor and product ions: 0.6–0.7 FWHM).
Ultrahigh purity argon was used as the collision gas at
a thickness of approximately 2.3 3 1014 atoms/cm2. The
collision energy (ELAB) was 30 V. The precursor/prod-
uct SRM transitions monitored were m/z 507 to m/z
161 for 5-FU (Figure 2), and m/z 509 to m/z 161 for
5-FU–15N2 using a 500 ms dwell time for each transition.
Because the analyte and internal standard produce
common product ions, it was necessary to prevent
“crosstalk” in SRM mode. The Sciex software was set to
Figure 1. Derivatization of 5-FU with BMC for LC-MS/MS
determination. The reaction yielded .95% of the diderivative.
(mw: molecular weight, RT: room temperature)
Figure 2. Full scan Q1 mass spectrum resulting from direct
infusion of the derivatization reaction solution containing 10
mg/mL of 5-FU (upper). Product ion mass spectrum of the
precursor ion at m/z 507 (lower). The product ion identified at
m/z 161 was used for SRM determination of derivatized 5-FU in
human plasma samples.
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invoke “Q2 Settling,” which “empties” the collision cell
before each transition is monitored by adjusting the
product ion mass to m/z 20 for 10% of the analytical
dwell time (50 ms in this case).
Preparation of Plasma Samples
Stock solutions of 5-FU and 5-FU–15N2 were prepared
in acetonitrile (1.00 mg/mL). The analytical spiking
solutions were prepared by serial dilution of the 5-FU
stock solution to provide a concentration range of 0.5 to
100 ng per 50 mL in acetonitrile. Internal standard
spiking solution was prepared in acetonitrile by dilut-
ing the 5-FU–15N2 stock solution to a working concen-
tration of 100 ng per 50 mL. Calibration standards, at
concentrations of 1, 5, 10, 50, 100, and 200 ng/mL, were
prepared in duplicate by adding 50 mL of the appropri-
ate 5-FU spiking solutions to 500-mL aliquots of drug-
free, control human plasma.
Pooled quality control (QC) samples were similarly
prepared at low (15 ng/mL), middle (75 ng/mL), and
high (150 ng/mL) concentrations from a stock solution
prepared with a separate weighing of 5-FU.
For each day of analysis, fresh calibration standards
were prepared and 500-mL aliquots of the QC and all
experimental (unknown) samples were pipetted. To
compensate for the acetonitrile added to the calibrations
standards, 50 mL of pure acetonitrile was added to each
QC and experimental sample. The internal standard
(100 ng) was then added to all samples.
Extraction
After adding internal standard, the samples were
treated with 2 mL of acetonitrile for protein precipita-
tion. After thorough vortex mixing (approximately 10 s
on a Vortex Genie mixer), 4 mL of ethyl acetate was
directly added to the samples. The test tubes were
capped and the samples were vortex mixed for 2 min
using an IKA-Vibrax-VXR vortex mixer. The samples
were then centrifuged at 5°C for 10 min at 3000 rpm.
The clear supernatant was decanted into a clean test
tube and evaporated to dryness at 35°C under nitrogen.
Derivatization
Derivatization reagent was freshly prepared each week
and stored at 4°C. The reagent was prepared by dis-
solving 20 mg of 4-bromomethyl-7-methoxycoumarin
and 40 mg of 18-crown-6 in 10 mL of dry acetone
(stored over 4 Å molecular sieves). Approximately 5 mg
of potassium carbonate, 100 mL of the derivatization
reagent, and 3 mL of dry acetone were added to each
extracted sample. The samples were capped and gently
vortexed for 20 min using an IKA-Vibrax-VXR vortex
mixer. The liquid was then transferred to another test
tube and dried at 35°C under nitrogen. Hexane (4 mL)
was added to wash the dried residue for 5 min using an
ultrasonicating bath. The hexane wash was discarded.
The samples were dried under nitrogen and reconsti-
tuted in 150 mL of acetonitrile: aqueous ammonium
acetate, 0.01 M, pH 4.5, (50:50, v/v). The reconstituted
samples were filtered prior to injection using 0.22 m
centrifuge filters. The filtrate (approximately 130 mL)
was transferred to autosampler vials and 40-mL aliquots
were injected onto the HPLC system.
Treatment of Data
All calculations were based on peak area ratios. The
chromatographic peak area of 5-FU was divided by the
peak area of the internal standard, 5-FU–15N2. Concen-
trations of 5-FU in the experimental and QC samples
were determined using the slope and intercept values
from a linear regression of the peak area ratio versus the
concentration values from the calibration standards. To
improve the accuracy of the assay throughout the lower
calibration range, the regressions were weighted 1/ra-
tio2.
Precision and Accuracy
The intraassay (within-day) precision and accuracy (%
theoretical) were assessed using QC samples. Five rep-
licates of each QC concentration were analyzed. To
evaluate precision, the mean value and percent relative
standard deviation (% RSD) were calculated for each
concentration. The accuracy was assessed by comparing
the mean concentration determined to the theoretical
concentration.
Interassay (between-day) precision was obtained
from the calibration standards and QC samples from
four sample batches analyzed on four separate days.
For each day of analysis, results for the five replicates of
each QC concentration were determined, and the du-
plicates for each calibration standard were obtained by
back calculation. The mean value for the QC samples
and the calibration standards for each day was then
compared across the four validation days to determine
the precision.
Recovery, Specificity, and Stability
Extraction recovery was determined from the radioac-
tivity distribution of 5-FU–2-14C using five replicates of
plasma samples at concentrations of 50 and 200 ng/mL.
To evaluate the specificity of the method, SRM
chromatograms of drug-free, control plasma from ap-
proximately six lots of human plasma were examined
for interfering peaks.
The stability of derivatized 5-FU in dry extracts and
in injection solvent was studied by comparing samples
after storage for five days under refrigeration (4°C) or
for 24 h at room temperature to freshly prepared QC
samples. Five replicates of the low, middle, and high
QC samples were used. The stability data were evalu-
ated by calculation of mean (geometric) differences
with 90% confidence intervals (CI).
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Results and Discussion
Sample Extraction
The extraction procedure used in this method can be
characterized as a “double precipitation” that included
two steps: an acetonitrile precipitation of plasma pro-
teins, and a further ethyl acetate precipitation of water
soluble endogenous material, such as peptides and
sugars. The solvent mixture of acetonitrile and ethyl
acetate in this proportion is miscible with 500 mL of
human plasma. This double precipitation resulted in
samples that were “cleaner” in both the physical and
analytical aspects than samples prepared with acetoni-
trile precipitation alone. Yet the procedure is simple
and rapid. Following brief mixing and centrifugation to
solidify the precipitated proteins, a decant and an
evaporation were all that was needed to prepare the
samples for derivatization.
Derivatization
Our previous attempts to develop an LC-MS/MS assay
for 5-FU without derivatization failed. We found that
5-FU had practically no response in positive ionization
mode using either APCI or electrospray ionization.
Although it had good response in negative ionization
APCI mode, we were unable to achieve the required
detection limits. A contributing factor was the unac-
ceptably high chemical background noise which we
routinely experienced. Following infusion of 5-FU, or
simply the injection of several high concentration cali-
bration standards, the chemical background noise grew
to a level greater than 5000 counts per second (CPS)
which dramatically reduced our detection limit. We
attributed this phenomenon to the 5-FU sticking in the
APCI interface and then constantly bleeding into the
ionization region, which created background signal.
Rigorous cleaning of the APCI probe and the mass
spectrometer interface region reduced this chemical
noise to acceptable levels (,100 CPS), but following the
analysis of higher concentration samples it would grad-
ually return and affect the performance of the assay. In
addition, we considered it prudent to tune the instru-
ment daily using an infusion of 5-FU or the internal
standard, but this was found impossible because of the
high chemical background that resulted. However, we
discovered that derivatization of 5-FU with 4-bromo-
methyl-7-methoxycoumarin (BMC) yielded a product
which eliminated this chemical background problem.
Presumably the chemistry of the analyte was suffi-
ciently altered to prevent it from adhering to compo-
nents in the APCI interface.
The choice of BMC as the derivatizing agent was
based on the following criteria. It was found to be:
inexpensive, readily commercially available in a puri-
fied form, and it reacted rapidly with 5-FU under
convenient conditions to yield a di-derivatized product
(Figure 1) that was chemically stable.
The derivatization procedure was designed to be
simple and nonhazardous. Crystalline potassium car-
bonate was added to the dried, extracted samples and
the amount was not critical. 3 to 8 mg was adequate for
the reaction and it was convenient to add this amount
with a small spatula. BMC and 18-crown-6 were dis-
solved in solution and added to the samples with a
repeating pipette. The 18-crown-6 was used in the
derivatization reaction to increase the solubility of po-
tassium carbonate by complexing with the potassium
ion in solution. This also enhanced the reaction rate and
yield. The reaction reached optimum yield after 20 min
at room temperature. Investigation using TLC with UV
detection revealed less than 5% of the monoderivative
was produced, and there was no unreacted 5-FU de-
tected. Any imprecision in the yield of mono- versus
di-product could lead to variability in the assay. This is
always a concern when derivatizing extracts of biolog-
ical samples where the matrix may be variable. How-
ever, any variability in derivatization was compensated
through the use of a stable isotope labeled internal
standard. Washing with hexane after derivatization was
helpful to remove lipophilic endogenous material and
derivatization by-products which tended to accumulate
on the HPLC column and degrade the chromatographic
performance over time.
MS/MS Analysis
The derivatized 5-FU produced an intense protonated
ion at m/z 507 under positive ionization APCI condi-
tions. Figure 2 depicts the full scan mass spectrum
(upper) resulting from direct infusion of the reaction
mixture. Not surprisingly, the spectrum contains the
protonated and potassium adduct ions of 18-crown-6.
Also evident is an ion at m/z 319, which was consistent
with the protonated mono-derivative of 5-FU. After
investigation, it was found the 25% abundance of the
mono-derivative was due to fragmentation of the di-
derivatized product in the mass spectrometer caused by
the orifice potential of 50 V (commonly called “up-front
CID”). When the orifice voltage was lowered to 35 V,
the intensity of m/z 319 was significantly reduced.
However, this did not lead to a corresponding increase
in sensitivity of the assay since the precursor ion at m/z
507 formed an adduct ion with ammonia from the
mobile phase with lower declustering potentials. There-
fore, an orifice setting of 50 V was the best compromise
to produce the highest abundance of the precursor ion.
The lower spectrum in Figure 2 depicts the product
ion spectrum of m/z 507. The ion at m/z 161 was used
for SRM determination of derivatized 5-FU. A fragmen-
tation scheme for the genesis of m/z 161 under MS/MS
conditions is proposed in Figure 3. The protonated
molecule at m/z 507 appears to fragment through
cleavage of one of the benyzlic C–N bonds resulting in
the ion observed at m/z 189. As depicted in the figure,
we can speculate this is a charge-induced fragmentation
process. The ion at m/z 189 then appears to liberate CO
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to yield the ion at m/z 161. The product ion observed in
Figure 2 (lower) at m/z 133 was postulated to have
arisen from liberation of another molecule of CO from
m/z 161.
It was analytically unfortunate that all of the major
product ions observed in Figure 2 (lower) appeared to
have their origin from ion current maintained in the
derivative part of the molecule. Ideally, a product ion
containing a portion of the parent molecule is a more
suited candidate for SRM determination because this
may confer higher specificity to the assay. However,
our considerable search for a suitable derivatization
agent for 5-FU failed to find a candidate which would
yield a product ion containing at least a portion of the
5-FU molecule.
Although not shown for the purpose of brevity, the
full scan and product ion mass spectra for derivatized
5-FU–15N2 were essentially identical. Similar to 5-FU,
the internal standard yielded a product ion at m/z 161,
which helped to confirm our proposed fragmentation
pathway. However, since both analytes produced iden-
tical product ions, and they co-eluted, it was necessary
to avoid “crosstalk” during SRM. Crosstalk arises when
product ions stay resident in the collision cell from one
precursor ion and are recorded when another precursor
ion is selected which produces the same product ion. To
prevent this situation, the Sciex RAD software (Routine
Acquisition and Display, ver. 2.6) was set to invoke “Q2
Settling” which effectively “empties” the collision cell
after each SRM transition is monitored. This eliminated
the crosstalk in the assay procedure and ensured accu-
racy of the data.
Chromatography
Without derivatization, 5-FU is very low molecular
weight (130 Da) and very hydrophilic, which makes
chromatographic separation under traditional reversed-
phase HPLC conditions very challenging. Typically,
underivatized 5-FU eluted isocratically from the col-
umns we tested with less than 10% organic modifier
(acetonitrile or methanol) in the mobile phase. The
retention time was also very sensitive to the organic
modifier. Only a 1% change in the composition of the
mobile phase caused significant changes in the reten-
tion time of 5-FU. In addition, the performance of the
columns tended to degrade quickly. Rapid build up of
less polar endogenous material from the biological
samples occurred on the column because of the low
concentration of organic modifier in the mobile phase.
However, derivatization of 5-FU with BMC produced a
much higher molecular weight product (506 Da), which
was much more lipophilic. The chromatographic per-
formance of the derivatized product was well suited to
quantitative assays. It produced sharp, symmetrical
peaks (Figure 4), which were approximately 20 s wide
at base for the highest calibration standard. The reten-
tion time was 1.4 min with a mobile phase containing
65% acetonitrile, and the peaks were well resolved from
the endogenous material eluting in the solvent front
(the capacity factor k9 was approximately 1.75). The
total runtime was 3.5 min per sample, which allowed a
reasonable throughput rate of 17 samples per h. Our
problems with short column lifetime were also elimi-
nated because of the higher concentration of acetonitrile
in the mobile phase (65% v/v).
Figure 4 shows representative SRM chromatograms
of drug-free, control plasma, a low calibration standard,
and a low QC sample. Note that extraneous peaks were
observed in the chromatograms. We attributed this to
monitoring a product ion that did not contain a portion
of the 5-FU molecule and that did not confer structural
specificity to 5-FU. The lower limit of quantitation was
reduced because an endogenous peak from plasma
eluted very close in retention time to derivatized 5-FU
(chromatogram A of Figure 4). Even though the method
was capable of higher sensitivity, we were compelled to
set the lower limit of quantitation at 1.0 ng/mL to
maintain at least a 4:1 signal-to-noise ratio with respect
to this small endogenous peak.
When the assay procedure was applied to routine
sample analysis, the chromatographic performance was
found to be very durable. After injection of over 800
biological samples on a single HPLC column, there was
no observable deterioration in column back pressure,
the chromatographic peak shape of the analytes, the
retention times, or the method specificity.
Validation and Performance
The intraassay (within-day) precision and accuracy data
are summarized in Table 1. This data was obtained from
QC samples on the first validation day. The intraassay
precision was found to be acceptable, with the %RSD
ranging from 1.5% to 3.9% for the three concentrations
of QC samples. The accuracy of the method was high,
with the % theoretical ranging from 99.1% to 104.3%.
The interassay (between-day) precision for the cali-
bration standards and QC samples is summarized in
Table 2. The interassay precision for the calibration
standards ranged from 0.0 to 3.5% and averaged 2.0%.
The interassay precision for the QC samples ranged
from 2.7% to 6.1% and averaged 4.2%. The overall
Figure 3. Proposed MS/MS fragmentation mechanism of deri-
vatized 5-FU: the protonated molecule at m/z 507 appears to
undergo cleavage of a benzylic C–N bond resulting in the product
ion observed at m/z 189 in Figure 2 (lower). This ion liberates CO
yielding the ion at m/z 161.
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interassay precision calculated from both the calibration
standards and the QC samples averaged 2.7%.
The dynamic range of this assay is 1.0 to 200 ng/mL
utilizing 500-mL aliquots of human plasma. However,
the six-point calibration curve was slightly nonlinear.
Because they co-eluted and generated a common prod-
uct ion, there was a small, unavoidable isotopic contri-
bution from 5-FU to the 5-FU–15N2 internal standard
due to naturally occurring 18O. This contribution aug-
mented the internal standard intensity in the upper
region of the calibration curve causing slight nonlinear-
ity. We minimized this effect by adding a high amount
of internal standard to the samples (100 ng). Rather than
using a nonlinear regression function, we chose to use
weighted linear regression (1/ratio2). This ensured ac-
curacy at the lower end of the calibration curve, and the
error committed in the upper region was analytically
acceptable: the accuracy of the highest QC concentra-
tion was 99.1% (Table 1) and the back-calculated 200
ng/mL calibration standard from Table 2 averaged
187.6 ng/mL (93.8% theoretical).
Summarized in Table 3 are the slope, intercept, and
correlation coefficient data from five validation days.
The slope showed good precision (3.2% RSD), but the
intercept data were considerably more variable (45.7%
RSD). Because the magnitude of the intercepts was
always very small, we considered the data acceptable in
spite of the variability. The correlation coefficient
showed good precision with 0.2% RSD.
Extraction recovery was obtained using radioactive
5-FU–2-14C. The recovery was determined to be 75.1%
and 77.1% for the 50 and 200 ng/mL concentrations,
respectively. We were unable to obtain data from lower
concentrations because of the low enrichment of the
5-FU–2-14C.
Derivatized 5-FU was stable both in the injection
solvent and when stored as dry plasma extracts. The
percent difference was limited to 4.38% among freshly
prepared QC samples, dry extracts refrigerated for 5
days, and reconstituted extracts stored at room temper-
ature for 24 h.
The method was found to be specific for the deter-
mination of 5-FU. No interferences were noted from
either endogenous components of plasma or from the
Figure 4. Representative SRM LC-MS/MS chromatograms of:
(A) control human plasma, (B) a low calibration standard, and (C)
the low QC sample at 15 ng/mL. The upper chromatogram in each
figure depicts the SRM for derivatized 5-FU and the lower is the
internal standard, 5-FU–15N2. The expected retention time for each
is marked in the chromatograms.
Table 1. Intraassay precision (% RSD) and accuracy (%







Replicate 1 14.70 79.80 148.3
Replicate 2 15.50 78.20 145.8
Replicate 3 16.40 77.50 150.8
Replicate 4 15.70 79.00 153.7
Replicate 5 15.40 76.80 144.4
Mean 15.54 78.26 148.6
SD 0.611 1.187 3.756
% RSD 3.93 1.52 2.53
% Theoretical 103.6 104.3 99.1
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anticoagulant (EDTA) across several lots of pooled
human plasma. Dihydro-5-fluorouracil and alpha-
fluoro-beta-alanine [14], metabolites of 5-FU, were also
found not to interfere. Any interference from another
5-FU metabolite, alpha-fluoro-beta-ureidopropionic
acid [14], was not verified because authentic reference
standard could not be obtained. However, because of
the chemical structure of the metabolite, interference
with the assay procedure was considered unlikely.
Conclusions
Over the past several years, assay procedures based on
LC/MS have become the analytical chemist’s dominant
tool for the analysis of molecules of pharmaceutical
interest. One reason for the decline in popularity
GC/MS procedures may be the frequent need to de-
rivatize analytes to impart volatility, which adds time
and complexity to a method. However, we have found
that derivatization technology can be very useful for
problem solving in LC/MS procedures for challenging
analytes. Keeping in mind today’s constant requirement
to analyze large numbers of samples quickly, we de-
signed the extraction and derivatization scheme in this
method to be simple and easy to perform, yet robust.
Derivatization with BMC changed the chemical nature
of 5-FU significantly, thereby improving the chromato-
graphic performance and eliminating our problem with
chemical background noise (“memory” effect) in the
APCI interface. These changes led to major improve-
ments in the performance of the assay compared to our
efforts with underivatized 5-FU.
This new assay for 5-FU was fully validated and the
specificity, precision, accuracy, and recovery were
found to be very good. In addition to its routine
application for the determination of 5-FU, this method
has been used on analysis of other uracil analogs with
only minor modifications [19].
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Day 1 1.0 5.0 10.2 52.0 103.0 187.8 16.2 71.1 149.2
Day 2 1.0 5.4 10.2 51.3 96.8 190.8 15.5 77.5 152.2
Day 3 1.0 5.1 10.7 52.5 96.3 188.9 15.3 77.1 147.8
Day 4 1.0 5.3 10.6 52.1 99.9 183.0 15.3 76.1 132.5
Mean 1.0 5.2 10.4 52.0 99.0 187.6 15.6 75.5 145.4
SD 0.000 0.183 0.263 0.499 3.106 3.323 0.427 2.959 8.810
% RSD 0.00 3.52 2.53 0.96 3.14 1.77 2.74 3.92 6.06
% Overall RSD STDs 1.99
% Overall RSD QCs 4.24
% Overall RSD of STDs and QCs 2.74
Table 3. Summary of slope, intercept, and correlation




Day 1 0.0178 0.0169 0.9967
Day 2 0.0173 0.0107 0.9977
Day 3 0.0185 0.00321 0.9956
Day 4 0.0172 0.0114 0.9960
Day 5 0.0172 0.0115 0.9933
Mean 0.0176 0.0107 0.9959
SD 0.000561 0.00489 0.00164
% RSD 3.19 45.70 0.16
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